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durability of plaque modification.
Methods: Patients with PAD underwent primary intervention with orbital technology
followed by low pressure balloon. Lesion compliance markers, including maximum
post-orbital balloon inflation pressures, inflation times, dissection rates and bail-out
stent rates, were recorded. 12-month reintervention rates were also tracked.
Results: 46 patients (74% male, 71 yrs) with 57 fibrotic or calcified lesions. Patient
demographics: diabetes (50%), renal disease (39.1%), CAD (67%), HTN (98%),
hyperlipidemia (94%), Rutherford 3-5. Lesion locations: CFA (9%), SFA (56%),
popliteal (19%) and tibial/peroneal (16%). Average pre-treatment stenosis was 89%.
In 84% of cases, balloon inflation was utilized to achieve a mean residual stenosis of
10.5%. Mean maximum inflation pressure was 5.3 atms for a mean of 2.3 min. 1
dissection was reported. No bail-out stenting was required. 5 patients (10.9%) returned
for re-treatment of the target lesion within the 12-month follow-up period.
Conclusion: In this study, the use of orbital technology modified lesion compliance
in resistant plaques as demonstrated by low pressure and short duration post-orbital
balloon inflations. Bail-out stenting was eliminated in this challenging patient
population, and use of orbital technology resulted in durable long-term results with a
low reintervention rate.
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Combination of Flexibility and Radial Strength Lead to Positive Outcomes in
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Background: The anatomies of patients treated with TEVAR are as diverse as the
pathologies that are being treated. Increased graft flexibility and conformability may
contribute to a device’s ability to adapt to these different anatomies and pathologies.
We report the worldwide experience of the Valiant thoracic stent graft (Medtronic
Vascular, Santa Rosa, Calif) in treatment across aortic pathologies.
Methods: Three major studies encompassing multiple pathologies are included in this
analysis. VALOR II: a 160 patient prospective, nonrandomized, pivotal trial conducted
in the US for the treatment of descending Thoracic Aneurysm (TAA) or degenerative
disease, The Valiant Captivia Registry: a 100 patient post market registry conducted
in Europe for the treatment of TAA or Aortic Dissection, and the VIRTUE Registry: a
100 patient prospective European registry for the treatment of acute, sub-acute, or
chronic dissection.
Results: Thirty day mortality across all studies was 3.1-4%. The incidence of stroke
at 30 days was 2.5 – 4% while spinal cord ischemia rates were less than 2%. There
were no Type 1a endoleaks reported in the VIRTUE cohort and 1.5% incidence in the
Valiant Captivia Registry group at 30 days. The incidence of Type 1 endoleak in the
VALOR II cohort was 3% at 1 year. Across all patients, there was only 1 rupture and
1 conversion which were attributed to the same patient.
Conclusion: Early results from the VALOR II Study, the Valiant Captivia Registry,
and the VIRTUE Registry demonstrate that the Valiant thoracic stent graft with its high
conformability is effective in treating a variety of thoracic aortic pathologies including
TAA and degenerative disease, as well as, acute, sub-acute, and chronic dissection.
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Background: To report registry data in which limb ischemia patients were treated with
mechanical thrombectomy.
Methods: A two-phase ongoing prospective registry of the MEDRAD Angiojet
catheter used in the treatment of acute and chronic limb ischemia was examined.
Electronic data capture case report forms were completed by site staff collecting
patient’s history, procedural information including adjunctive treatments, outcomes
and adverse events. Phase I patients were followed to 3 months post procedure while
the ongoing phase II patients will be followed for 12 months.
Results: Currently 271 patient with acute (200/271; 74%) and chronic (71/271; 26%)
limb ischemia at 42 centers have been treated (160 male and 111 female, mean age 66;
range 21 to 96 years). All patients were treated with the Angiojet catheter, with 63%
receiving lytic delivery by the AngioJet. CDT occurred in 45%. Full patency was
achieved in 82% with a statistically significant improvement in ABIs (p<0.0001). Initial
hospitalization AEs included: bleeding requiring transfusions 10/271 (4%), bypass
surgery (11/271 (4%) and amputation 9/271 (3%). Of the 80% (218/271) with 3 month
follow ups, 7/271 (3%) reported bypass surgery and another 6/271 (6%) had an
amputation. The physical and mental QOL scores improved from baseline 37% and
11%, respectively. A 93% (124/133) limb salvage rate was reported for the acute limb
ischemia patients with baseline Rutherford classifications of IIa, IIb and III.
Conclusion: Mechanical thrombectomy combined with adjunctive treatments is an
effective and safe strategy for limb ischemia.
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Background: Arterial aneurysms are traditionally treated surgically, but more and
more by interventional procedures using covered stents Endografts or coils with a high
technical success rate, but some problems are not solved like protection of aneurysm
rupture, endoleaks, stent thrombosis. We developed a new concept of stent, the
Multilayer stent (M.S) to treat aneurysms and try to avoid some drawbacks encountered
with endografts.
Methods: This M.S is a 3 Dimensional braided tube made of several interconnected
layers without any covering. Our earliest tests in vitro (theorical simulation,
computerized Fluid dynamics, Molecular Modelization) and in vivo tests demonstrate
that this MS reduces the velocity in the aneurismal sac up to 90% by modifying the
hemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the flow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this M.S preserves
the collateral branches allowing the possibility to cover any artery without
compromising the flow (renal, digestive arteries, supra aortic vessels …)
Results: 32 peripheral aneurysms (iliac:20, femoral:1, popliteal:4, renal:6,
mesenteric:1) were treated with the M.S, (male:25, mean age 61+/-8y) (42 stents Ø 5
to 14mm; length 40 to 100 mm) were implanted to treat these aneurysms, by femoral
approach. Technical success in all patients. No complications. All aneurysms
thrombosed with diameter reduction in some patients. 6 month to 30 month follow up
will be presented and we will discuss the time needed to achieve exclusion and the
factors influencing this exclusion. Allthe side branches remained patent.
Conclusion: A new concept of stent,is developed to treat aneurysm. It opens a new
approach to treat peripheral aneurysms avoiding most of the complications encountered
with current endovascular techniques. The results obtained seem promising. A larger
study is ongoing.
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Background: Conventional balloon angioplasty in Superficial femoral and popliteal
artery territories is associated with a high restenosis rates 12 months post-procedure.
Recent clinical data have suggested that use of DEBs may substantially reduce
restenosis. The impact of InPact Admiral(Medtronic Invatec, Roncadelle, Italy)DEB
use on provisional stenting and 12 month clinical outcomes in routine clinical practice
is described.
Methods: This prospective, observational registry enrolled patients with Rutherford
class 2, 3, or 4 femoropoliteal arterial disease with reference vessel diameter of 3 to 7
mm and lesion or occlusion length ≤15 cm. Endpoints included restenosis rate, target
lesion revascularization (TLR), and change in Rutherford class and ankle-brachial
index (ABI). Walking capacity and quality of life (QOL) were also assessed
Results: At 12 months follow up, 105 patients (114 lesions) were evaluable. Baseline
ABI was 0.56 ± 0.15. Baseline Rutherford classification was 26.7% for class 2, 64.8%
for class 3, and 7.6% for class 4. Most lesions were located in the middle and distal
superficial femoral artery (77.1%). The device was successfully deployed in all patients
and only 12.3% of lesions required stenting. The rate of TLR was 8.7% at 12 months.
QOL and functional status were substantially improved at all time points with 88% in
Rutherford class 0 or 1, and a mean ABI of 0.81 ± 0.4 at 12 months
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